DDrare: Database of Drug Development for Rare Diseases

159. 色素性乾皮症
［臨床試験数：5，薬物数：13（DrugBank：4），標的遺伝子数：4，標的パスウェイ数：13］

Searched query = "Xeroderma pigmentosum", "XP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Ipilimumab; Isotretinoin; Liposomal T4N5 lotion; Nivolumab; Procedure: Biospecimen Collection; TRABECTEDINA; Trabectedina; Trabectedine; YONDELIS 0,25 mg polvo para concentrado para solución para perfusión; YONDELIS 1 mg polvo para concentrado para solución para perfusión; Yondelis; Yondelis 0.25 mg powder for concentrate for solution for infusion.; Yondelis 1 mg powder for concentrate for solution for infusion.

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00002811 (ClinicalTrials.gov)	July 1996	1/11/1999	T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum	A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES	Precancerous Condition	Drug: liposomal T4N5 lotion	Applied Genetics	NULL	Active, not recruiting	2 Years	60 Years	Both	30	Phase 3	United States;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00002811
(ClinicalTrials.gov)

July 1996

1/11/1999

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES

Precancerous Condition

Drug: liposomal T4N5 lotion

Applied Genetics

NULL

Active, not recruiting

2 Years

60 Years

Both

Phase 3

United States;Germany;United Kingdom